These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17179897)

  • 1. Sitagliptin (Januvia) for type 2 diabetes.
    Med Lett Drugs Ther; 2007 Jan; 49(1251):1-3. PubMed ID: 17179897
    [No Abstract]   [Full Text] [Related]  

  • 2. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
    Green BD; Flatt PR; Bailey CJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
    Winkler G
    Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
    Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
    Aaboe K; Akram S; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2015 Jan; 17(1):74-81. PubMed ID: 25243647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.
    Deacon CF
    Expert Opin Investig Drugs; 2007 Apr; 16(4):533-45. PubMed ID: 17371200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of sitagliptin phosphate: a novel treatment for type 2 diabetes.
    Gallwitz B
    Vasc Health Risk Manag; 2007; 3(2):203-10. PubMed ID: 17580730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.
    Gagliardino JJ; Santoro S; Arellano S; Di Girolamo G
    Expert Opin Pharmacother; 2008 Jun; 9(9):1495-507. PubMed ID: 18518780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.
    Herman GA; Stein PP; Thornberry NA; Wagner JA
    Clin Pharmacol Ther; 2007 May; 81(5):761-7. PubMed ID: 17392725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatments for diabetes.
    Bloomgarden ZT; Inzucchi SE
    N Engl J Med; 2007 May; 356(21):2219-20; author reply 2222-3. PubMed ID: 17522409
    [No Abstract]   [Full Text] [Related]  

  • 13. Finding new treatments for diabetes--how many, how fast... how good?
    Nathan DM
    N Engl J Med; 2007 Feb; 356(5):437-40. PubMed ID: 17267901
    [No Abstract]   [Full Text] [Related]  

  • 14. [Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2].
    Musch A; Heinzl S
    Med Monatsschr Pharm; 2007 Aug; 30(8):282-6; quiz 287-8. PubMed ID: 17879807
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
    Nauck MA; Meininger G; Sheng D; Terranella L; Stein PP;
    Diabetes Obes Metab; 2007 Mar; 9(2):194-205. PubMed ID: 17300595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sitagliptin.
    Lyseng-Williamson KA
    Drugs; 2007; 67(4):587-97. PubMed ID: 17352516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sitagliptin: a viewpoint by Mark S. Kipnes.
    Kipnes MS
    Drugs; 2007; 67(4):598-9. PubMed ID: 17352517
    [No Abstract]   [Full Text] [Related]  

  • 18. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
    Abel T; Fehér J
    Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New combination treatments in the management of diabetes: focus on sitagliptin-metformin.
    Green J; Feinglos M
    Vasc Health Risk Manag; 2008; 4(4):743-51. PubMed ID: 19065992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.
    Aschner P; Kipnes MS; Lunceford JK; Sanchez M; Mickel C; Williams-Herman DE;
    Diabetes Care; 2006 Dec; 29(12):2632-7. PubMed ID: 17130196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.